Francis Medical Expands Commercial Reach of Vanquish Water Vapor Ablation for Prostate Patients in Southeast

Francis Medical Expands Commercial Reach in the Southeast

Francis Medical, a company focused on innovative urological cancer treatments, is making significant strides with its Vanquish® Water Vapor Ablation system. Recently, they announced the commencement of commercial procedures aimed at targeting prostate tissue in the Southeast region of the United States. This marks a crucial step in their expansion efforts following FDA clearance in late 2025.

The recently performed procedures were conducted by renowned urologists, Dr. Neal Patel and Dr. Jason Lomboy, at surgery centers in Johns Creek and Marietta, Georgia. Patients, diagnosed with localized prostate cancer, benefited from this minimally invasive technology that utilizes a unique water vapor approach for tissue ablation. The introduction of the Vanquish system into routine clinical practice is a significant advancement, driven by promising clinical data from the ongoing VAPOR 2 pivotal study.

Dr. Patel emphasized the importance of clinical validation when adopting new technologies into medical practice. He stated, "Adopting new technologies into everyday practice requires both clinical validation and operational readiness. Vanquish offers a streamlined approach to focal therapy that aligns with our goal of delivering a safe and effective procedure while minimizing the impact on patients' quality of life."

What sets the Vanquish system apart is its novel approach to prostate tissue ablation. Unlike traditional methods, which may involve invasive surgery and radiation—both of which can compromise surrounding structures crucial for maintaining erectile function and urinary control—the Vanquish technique employs high-energy, sterile water vapor. This targeted method aims to confine the thermal energy strictly within the prostate's natural boundaries, thus offering a less disruptive alternative for patients.

Early clinical results from the VAPOR 2 study have been encouraging. After six months, 91% of patients achieved clearance from clinically significant in-field disease, demonstrating the effectiveness of the treatment. Moreover, side effects typically associated with prostate cancer treatments—as evidenced by no serious adverse events related to the device and low rates of urinary incontinence and erectile dysfunction—reinforce the safety profile of the Vanquish system.

Dr. Lomboy noted, "Early clinical data from the VAPOR 2 study suggests that this approach can deliver meaningful prostate tissue ablation with a favorable safety profile. Patients have reported minimal discomfort and high satisfaction following their procedure, reinforcing our confidence in adding this technology to our minimally invasive options in prostate care as we continue to evaluate longer-term outcomes."

This expansion signifies an important milestone for Francis Medical as they work diligently to introduce the Vanquish system into real-world clinical settings. Mike Kujak, the President and CEO of Francis Medical, remarked, "These procedures mark an important step forward in introducing Vanquish into real-world clinical practice. We remain focused on a disciplined launch working closely with physicians who are dedicated to advancing patient care through innovation."

The Vanquish Water Vapor Ablation System is designed to safely perform thermal ablation of targeted prostate tissue via a transurethral procedure. However, it is critical to note that the FDA has not evaluated the Vanquish system for treating prostate cancer or any long-term outcomes related to such treatments.

Francis Medical was founded by Michael Hoey, as a tribute to his father, who endured painful treatments for prostate cancer. The company is committed to delivering compassionate and innovative therapies that minimize life-altering side effects, striving to change the narrative around prostate cancer care.

For patients considering new treatment options, the Vanquish technology represents a promising advancement in the field of urology, potentially leading to improved outcomes and quality of life for those affected by prostate cancer.

For more information on Francis Medical and the Vanquish system, please visit Francis Medical's website or call their office at (763) 951-0370.